Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)
Open Access
- 30 October 2023
- journal article
- review article
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 13 (3) , 33-39
Abstract
Currently, there are three drugs in the world for the pathogenetic therapy of spinal muscular atrophy 5q: nusinersen, risdiplam and onasemnogene abeparvovek. At the same time, it is still unknown to what extent this treatment is able to change the natural history of the disease, and the development of methods for evaluating the effectiveness of treatment is the subject of active scientific research. This article is a review of studies of laboratory approaches for assessing the disease severity and the response to nusinersen therapy in patients with spinal muscular atrophy 5q in various age groups.Keywords
This publication has 43 references indexed in Scilit:
- A new biomarker candidate for spinal muscular atrophy: Identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron proteinPLOS ONE, 2018
- Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported casesNeuromuscular Disorders, 2018
- miRNA in spinal muscular atrophy pathogenesis and therapyJournal of Cellular and Molecular Medicine, 2017
- Revisiting biomarker discovery by plasma proteomicsMolecular Systems Biology, 2017
- Neurofilaments and Neurofilament Proteins in Health and DiseaseCold Spring Harbor Perspectives in Biology, 2017
- A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy ControlsPLOS ONE, 2016
- Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy ControlsPLOS ONE, 2015
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- Creatine and Creatinine MetabolismPhysiological Reviews, 2000